| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2014PLoSO...9j4413B |
| P356 | DOI | 10.1371/JOURNAL.PONE.0104413 |
| P8608 | Fatcat ID | release_vtmvihsirjazlhpq6gs7ndjvai |
| P932 | PMC publication ID | 4152178 |
| P698 | PubMed publication ID | 25180793 |
| P5875 | ResearchGate publication ID | 265299452 |
| P50 | author | Harper L Wilson | Q100959537 |
| P2093 | author name string | Bing Zhou | |
| Jen Jen Yeh | |||
| Mingqing Li | |||
| William Y Kim | |||
| Bhavani Krishnan | |||
| Sean T Bailey | |||
| Jeffrey S Damrauer | |||
| Aleisha M Smith | |||
| P2860 | cites work | The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer | Q54535188 |
| Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2 | Q21145847 | ||
| The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis | Q22009936 | ||
| Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton | Q24299873 | ||
| The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation | Q24616946 | ||
| State of the science: an update on renal cell carcinoma | Q24630685 | ||
| mTOR signaling in growth control and disease | Q24634174 | ||
| Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth | Q24800550 | ||
| mTOR kinase structure, mechanism and regulation | Q27677954 | ||
| Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers | Q27851457 | ||
| Comprehensive molecular characterization of clear cell renal cell carcinoma | Q27852374 | ||
| Cancer statistics, 2013 | Q27860762 | ||
| Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function | Q28140184 | ||
| Defining the role of mTOR in cancer | Q28235431 | ||
| Identification of Regulatory Phosphorylation Sites in Mitogen-activated Protein Kinase (MAPK)-activated Protein Kinase-1a/p90 That Are Inducible by MAPK | Q28259117 | ||
| mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt | Q29547767 | ||
| Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer | Q29618030 | ||
| Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial | Q29618031 | ||
| Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma | Q29618608 | ||
| Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. | Q33880227 | ||
| The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma | Q34001234 | ||
| Different patterns of Akt and ERK feedback activation in response to rapamycin, active-site mTOR inhibitors and metformin in pancreatic cancer cells | Q34600369 | ||
| Synergistic effects of concurrent blockade of PI3K and MEK pathways in pancreatic cancer preclinical models | Q35018805 | ||
| Genetic and Functional Studies Implicate HIF1α as a 14q Kidney Cancer Suppressor Gene | Q35452783 | ||
| Augmentation of NVP-BEZ235's anticancer activity against human lung cancer cells by blockage of autophagy | Q35556966 | ||
| Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer | Q35895370 | ||
| Role of VHL gene mutation in human cancer | Q35990141 | ||
| The PP242 mammalian target of rapamycin (mTOR) inhibitor activates extracellular signal-regulated kinase (ERK) in multiple myeloma cells via a target of rapamycin complex 1 (TORC1)/eukaryotic translation initiation factor 4E (eIF-4E)/RAF pathway and | Q36052399 | ||
| Molecular pathways in renal cell carcinoma--rationale for targeted treatment | Q36625166 | ||
| Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models | Q37024819 | ||
| mTOR pathway in renal cell carcinoma | Q37086022 | ||
| Dual blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth in vitro and in vivo. | Q37281508 | ||
| The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer | Q37299263 | ||
| Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy | Q37389181 | ||
| TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in BRAF- Mutant Melanoma | Q37401151 | ||
| Progress of molecular targeted therapies for advanced renal cell carcinoma. | Q38149133 | ||
| Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors | Q39099207 | ||
| The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition | Q39380338 | ||
| Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas | Q39384830 | ||
| Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin | Q39827828 | ||
| Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors. | Q40585447 | ||
| A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1. | Q40875073 | ||
| AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity | Q43211411 | ||
| Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein | Q44043145 | ||
| In vivo activity of combined PI3K/mTOR and MEK inhibition in a Kras(G12D);Pten deletion mouse model of ovarian cancer | Q45842339 | ||
| The pharmacology of mTOR inhibition | Q46041824 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | e104413 | |
| P577 | publication date | 2014-09-02 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | mTOR inhibition induces compensatory, therapeutically targetable MEK activation in renal cell carcinoma | |
| P478 | volume | 9 |
| Q90459618 | Genomic and pathological heterogeneity in clinically diagnosed small cell lung cancer in never/light smokers identifies therapeutically targetable alterations |
| Q38778675 | MiR-144 inhibits cell proliferation of renal cell carcinoma by targeting MTOR. |
| Q47547587 | Naturally Occurring Canine Melanoma as a Predictive Comparative Oncology Model for Human Mucosal and Other Triple Wild-Type Melanomas. |
| Q47157452 | Prognostic value of copper transporter 1 expression in patients with clear cell renal cell carcinoma |
| Q48123819 | RAPTOR up-regulation contributes to resistance of renal cancer cells to PI3K-mTOR inhibition. |
| Q38788920 | Resveratrol Potentiates Growth Inhibitory Effects of Rapamycin in PTEN-deficient Lipoma Cells by Suppressing p70S6 Kinase Activity |
| Q36604270 | Synergistic roles of p53 and HIF1α in human renal cell carcinoma-cell apoptosis responding to the inhibition of mTOR and MDM2 signaling pathways |
| Q37462300 | Synergistic targeted inhibition of MEK and dual PI3K/mTOR diminishes viability and inhibits tumor growth of canine melanoma underscoring its utility as a preclinical model for human mucosal melanoma. |
| Q38885079 | The epidermal growth factor receptor pathway in chronic kidney diseases |
| Q33591361 | The selective MEK1 inhibitor Selumetinib enhances the antitumor activity of everolimus against renal cell carcinoma in vitro and in vivo |
Search more.